Markers of T-cell dysfunction and not inflammaging predict the waning of humoral responses to SARS-CoV-2 mRNA booster vaccination in people with HIV.
Humans
HIV Infections
/ immunology
Male
Female
Prospective Studies
COVID-19
/ immunology
Middle Aged
COVID-19 Vaccines
/ immunology
Antibodies, Viral
/ blood
Longitudinal Studies
Adult
Immunization, Secondary
Immunity, Humoral
SARS-CoV-2
/ immunology
Biomarkers
/ blood
T-Lymphocytes
/ immunology
CD4-CD8 Ratio
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
15 Nov 2024
15 Nov 2024
Historique:
received:
10
07
2024
accepted:
03
09
2024
medline:
30
10
2024
pubmed:
30
10
2024
entrez:
30
10
2024
Statut:
ppublish
Résumé
In this prospective longitudinal study, we evaluated the durability of humoral responses to SARS-CoV-2 mRNA booster vaccination in 93 people with HIV, exploring the possible role of T-cell dysfunction and inflammaging biomarkers in predicting antibody waning. We found that, despite a negligible influence of the inflammaging milieu, low CD4/CD8 ratio and CD4+CD127+ percentage as well as high CD8+CD38+CD45RO+ percentage are associated with faster antibody waning, in turn contributing to our understanding of the determinants of COVID-19 vaccine-elicited immune response in this population.
Identifiants
pubmed: 39474654
doi: 10.1097/QAD.0000000000004010
pii: 00002030-202411150-00016
doi:
Substances chimiques
COVID-19 Vaccines
0
Antibodies, Viral
0
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1987-1990Informations de copyright
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
Augello M, Bono V, Rovito R, Tincati C, Marchetti G. Immunologic interplay between HIV/AIDS and COVID-19: adding fuel to the flames?. Curr HIV/AIDS Rep 2023; 20:51–75.
Giacomelli A, Gagliardini R, Tavelli A, De Benedittis S, Mazzotta V, Rizzardini G, et al. Risk of COVID-19 in-hospital mortality in people living with HIV compared to general population according to age and CD4 strata: data from the ICONA network. Int J Infect Dis 2023; 136:127–135.
Peluso MJ, Antar AAR. Long COVID in people living with HIV. Curr Opin HIV AIDS 2023; 18:126–134.
Martín-Iguacel R, Moreno-Fornés S, Bruguera A, Aceitón J, Nomah DK, González-Cordón A, et al. Major cardiovascular events after COVID-19 in people with HIV. Clin Microbiol Infect 2024; 30:674–681.
Augello M, Bono V, Rovito R, Tincati C, d’Arminio Monforte A, Marchetti G. Six-month immune responses to mRNA-1273 vaccine in combination antiretroviral therapy treated late presenter people with HIV according to previous SARS-CoV-2 infection. AIDS 2023; 37:1503–1517.
Sette A, Crotty S. Immunological memory to SARS-CoV-2 infection and COVID-19 vaccines. Immunol Rev 2022; 310:27–46.
Costiniuk CT, Lee T, Singer J, Galipeau Y, Arnold C, Langlois MA, et al. Correlates of breakthrough SARS-CoV-2 infections in people with HIV: results from the CIHR CTN 328 study. Vaccines 2024; 12:447.
Antinori A, Cicalini S, Meschi S, Bordoni V, Lorenzini P, Vergori A, et al. Humoral and cellular immune response elicited by mRNA vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in people living with human immunodeficiency virus receiving antiretroviral therapy based on current CD4 T-Lymphocyte count. Clin Infect Dis 2022; 75:e552–e563.
Vergori A, Tavelli A, Matusali G, Azzini AM, Augello M, Mazzotta V, et al. SARS-CoV-2 mRNA vaccine response in people living with HIV according to CD4 count and CD4/CD8 ratio. Vaccines 2023; 11:1664.
Montesi G, Augello M, Polvere J, Marchetti G, Medaglini D, Ciabattini A. Predicting humoral responses to primary and booster SARS-CoV-2 mRNA vaccination in people living with HIV: a machine learning approach. J Transl Med 2024; 22:432.
Nasi M, De Biasi S, Gibellini L, Bianchini E, Pecorini S, Bacca V, et al. Ageing and inflammation in patients with HIV infection. Clin Exp Immunol 2017; 187:44–52.
McKittrick N, Frank I, Jacobson JM, White CJ, Kim D, Kappes R, et al. Improved immunogenicity with high-dose seasonal influenza vaccine in HIV-infected persons: a single-center, parallel, randomized trial. Ann Intern Med 2013; 158:19–26.
Berger CT, Greiff V, Mehling M, Fritz S, Meier MA, Hoenger G, et al. Influenza vaccine response profiles are affected by vaccine preparation and preexisting immunity, but not HIV infection. Hum Vaccin Immunother 2015; 11:391–396.
Avelino-Silva VI, Miyaji KT, Hunt PW, Huang Y, Simoes M, Lima SB, et al. CD4/CD8 ratio and KT ratio predict yellow fever vaccine immunogenicity in HIV-infected patients. PLoS Negl Trop Dis 2016; 10:e0005219.
Tian Y, Hua W, Wu Y, Zhang T, Wang W, Wu H, et al. Immune response to hepatitis B virus vaccine among people living with HIV: a meta-analysis. Front Immunol 2021; 12:745541.
Fuster D, Cheng DM, Quinn EK, Armah KA, Saitz R, Freiberg MS, et al. Inflammatory cytokines and mortality in a cohort of HIV-infected adults with alcohol problems. AIDS 2014; 28:1059–1064.
Ron R, Martínez-Sanz J, Herrera S, Ramos-Ruperto L, Díez A, Sainz T, et al. CD4/CD8 ratio and CD8+ T-cell count as prognostic markers for non-AIDS mortality in people living with HIV. A systematic review and meta-analysis. Front Immunol 2024; 15:1343124.
Kiazyk SA, Fowke KR. Loss of CD127 expression links immune activation and CD4(+) T cell loss in HIV infection. Trends Microbiol 2008; 16:567–573.
Bofill M, Mocroft A, Lipman M, Medina E, Borthwick NJ, Sabin CA, et al. Increased numbers of primed activated CD8+CD38+CD45RO+ T cells predict the decline of CD4+ T cells in HIV-1-infected patients. AIDS 1996; 10:827–834.
Alexandrova Y, Yero A, Mboumba Bouassa RS, Comeau E, Samarani S, Brumme ZL, et al. SARS-CoV-2 vaccine-induced T-cell response after three doses in people living with HIV on antiretroviral therapy compared to seronegative controls (CTN 328 COVAXHIV study). Viruses 2023; 15:575.
Bordoni V, Casale M, Pinto VM, Carsetti R, Gianesin B, Gamberini MR, et al. Inflammatory and senescence-associated mediators affect the persistence of humoral response to COVID-19 mRNA vaccination in transfusion-dependent beta-thalassemic patients. Am J Hematol 2023; 98:E145–E147.
Aaron T, Laudermilch E, Benet Z, Ovando LJ, Chandran K, Fooksman D. TNF-α limits serological memory by disrupting the bone marrow niche. J Immunol 2023; 210:595–608.
Pozo-Balado MDM, Bulnes-Ramos Á, Olivas-Martínez I, Garrido-Rodríguez V, Lozano C, Álvarez-Ríos AI, et al. Higher plasma levels of thymosin-α1 are associated with a lower waning of humoral response after COVID-19 vaccination: an eight months follow-up study in a nursing home. Immun Ageing 2023; 20:9.